Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation
Open Access
- 1 December 2017
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 248, 232-238
Abstract
No abstract availableKeywords
Funding Information
- Instituto de Salud Carlos III (RD012/0042/0001, RD012/0042/0002, RD012/0042/0015, RD012/0042/0044, RD12/0042/0029, RD012/0042/0066, RD12/0042/0069)
- Ministry of Economy and Competitiveness (SAF2015-71863-REDT)
- Bristol-Myers Squibb/Pfizer (CV185-419)
- FEDER
This publication has 21 references indexed in Scilit:
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEP Europace, 2016
- Prediction of Thrombo-Embolic Risk in Patients with Hypertrophic Cardiomyopathy (HCM Risk-CVA)European Journal of Heart Failure, 2015
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic reviewHeart, 2013
- Health status of cardiac genetic disease patients and their at-risk relativesInternational Journal of Cardiology, 2013
- 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathyThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Hypertrophic CardiomyopathyJAMA, 2002